ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress
ASLAN Pharmaceuticals Limited - American Depositary Shares (ASLN)
US:NASDAQ Investor Relations:
ir.aslanpharma.com
Company Research
Source: GlobeNewswire
SINGAPORE, July 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on varlitinib has been accepted for poster presentation at the upcoming 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain on 27 September - 1 October 2019. The abstract accepted for poster presentation (Abstract #1311), titled “A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors” will be presented by Dr. Aaron Tan. Varlitinib is a highly potent pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. At ESMO, new data will be presented from a phase 1 study to determine the safety and maximum tolerated dose (MTD) of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) up to 9 cycles fo
Show less
Read more
Impact Snapshot
Event Time:
ASLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASLN alerts
High impacting ASLAN Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASLN
News
- ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? [Yahoo! Finance]Yahoo! Finance
- Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders [Yahoo! Finance]Yahoo! Finance
ASLN
Analyst Actions
- 4/15/24 - HC Wainwright
ASLN
Sec Filings
- 4/12/24 - Form 424B5
- 4/12/24 - Form 6-K
- 4/12/24 - Form S-8
- ASLN's page on the SEC website